De’ Longhi Group – 6.6% Growth at Constant Exchange Rates and Accelerated Net Profit: Solid Results Fully Support Guidance May 12, 2026 The Group closed another quarter with robust organic growth, driven by the excellent expansion of the professional division, with turnover growing significantly and representing 18% of the Group's total for the period, and by the positive performance of the household
ASOS shares soar as it offloads Lichfield warehouse to M&S in £66m deal May 11, 2026 Retail giant ASOS agreed to sell one of its stock warehouses to Marks and Spencer for £66m in the latest sign of its efforts to save money on rent and improve its financial position. The fashion retailer said the sale of the Lichfield fulfilment centre, which is expected to close by the second half of [...]
Iran war costs Next £47m and may drive up prices May 6, 2026 Retail giant Next has said the ongoing disruption caused by the Iran War has hit it with a £47m increase in costs from climbing energy and transport prices. The FTSE 100 retail and homeware company said that the £27m increase, a sharp rise from it’s previous forecast of £15m, relates mainly to spikes in energy [...]
Fluidra Delivers a Good Start to 2026, Consistent With Full-year Expectations May 6, 2026 Sales up 5% at constant currency to €564 million, with growth across all regions driven by volume and price Net profit up 6.4% at constant currency to €46 million Fluidra maintains full-year guidance while monitoring dynamic trading environment
Lone Star Funds Completes Sale of novobanco to BPCE April 30, 2026 Nani Holdings S.à. r.l., an affiliate of Lone Star Funds (“Lone Star”), today announced it has successfully completed the sale of its majority stake in Novo Banco, S.A. (“novobanco” or “the bank”), Portugal’s fourth-largest bank, to BPCE, a leading European banking institution. Pursuant to the purchase price mechanism agreed to in the June 2025 Memorandum [...]
Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition Highlights April 23, 2026 Strong FY2025 financial and sustainability results; leadership transition will support continuity and long-term growth Revenue up 8.2% to €3.6bn with double-digit growth in Rare Diseases and U.S. market Air sales at €1.886bn, growing 3.9% vs. 2024 - Care sales at €904m growing 13.3% vs. 2024 - Rare sales at €906m, growing 22.3% vs. 2024 Giuseppe Accogli leaving to pursue another opportunity, Group CFO Jean-Marc Bellemin named Interim CEO while new CEO search is underway Record €885m Research & Development (R&D) investment underscores continued commitment to innovation across respiratory, rare disease and specialty care Sustainability leadership further strengthened through B Corp recertification and progress on Carbon Minimal Inhaler (CMI) innovation
TITAN Group: Full Year Results 2025 March 19, 2026 Very strong performance delivers another record year
REPLY: The Board of Directors Approved the Draft Financial Statements for the Year 2025 March 12, 2026 All economic indicators are positive. Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024); EBITDA at €467.6 million (€410.6 million in 2024); EBIT at €391.7 million (€330.4 million in 2024) Group net profit at €250.9 million (€211.1 million in 2024) Approval of the proposed dividend distribution of €1.35 per share.
Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy March 9, 2026 Coramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3 Prothena has now earned $150 million to date of the $1.2 billion total eligible milestone payments from Novo Nordisk
Bureau Veritas: Sector-Leading Organic Revenue Growth of 6.5% in FY 2025 February 25, 2026 Strong margin improvement to 16.3% in FY 2025 Positive growth outlook with continued margin expansion in 2026 New EUR 200 million share buyback